ANAB Spins Off First Tracks Biotherapeutics; Execs Depart
ANAPTYSBIO, INC filed a 10-K/A to amend its annual report, including corporate governance and executive compensation details. The company completed the spin-off of its subsidiary, First Tracks Biotherapeutics, Inc., on April 20, 2026, distributing all outstanding shares as a pro rata dividend. In connection with this spin-off, three executives, including two named executive officers for 2025 (Paul Lizzul and Dennis Mulroy), separated from the company. Additionally, the Board of Directors was reclassified on April 27, 2026, to ensure equal apportionment among its three classes following the departure of four members. The filing also detailed 2025 executive compensation and non-employee director compensation.
Key Highlights
- ANAB completed the spin-off of First Tracks Biotherapeutics, Inc. on April 20, 2026.
- Three executives, including 2025 NEOs Paul Lizzul and Dennis Mulroy, departed due to the spin-off.
- Board of Directors reclassified on April 27, 2026, for equal apportionment after four departures.
- Susannah Gray joined the Board in March 2026; John Orwin became Chairman in September 2023.
- 2025 Say-on-Pay vote received approximately 73% stockholder approval.
- Non-employee directors received annual cash retainers up to $40,000 in 2025.
- Non-employee directors received annual equity grants of 16,510 stock options and 6,030 RSUs.
- Imsidolimab was out-licensed to Vanda Pharmaceuticals in 2025.
Price Impact
More from ANAB